Sirna Therapeutics to Remain Listed on Nasdaq National Market
Thursday May 22, 8:55 am ET
BOULDER, Colo., May 22 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI - News) announced today that it has been informed by Nasdaq that Sirna's common stock will continue to be listed on The Nasdaq National Market. In a notification to Sirna, the Nasdaq Listing Qualifications Panel stated that after careful review it had determined that Sirna meets all the requirements for continued listing on The Nasdaq National Market.
"We are pleased that this uncertainty has been resolved. We believe that continued listing of our common stock on The Nasdaq National Market is in the best interest of the company and our stockholders," commented Howard W. Robin, President and Chief Executive Officer of Sirna Therapeutics.
Sirna Therapeutics has revised its strategy and implemented a number of actions that were designed to enhance its overall business and strengthen its equity position. The company recently completed a $48 million private financing with several leading venture capital investors.
About Sirna Therapeutics
Sirna Therapeutics is a biotechnology company leveraging its expertise in nucleic acid technology to develop and commercialize products that target human diseases. Sirna Therapeutics' primary focus is to develop therapeutics based on a nucleic acid technology called ribonucleic acid interference, or RNAi. Sirna Therapeutics is listed on the Nasdaq National Market under the ticker symbol "RNAI." More information on Sirna Therapeutics is available on the company's web site at www.sirna.com .
This press release contains forward-looking statements that involve risks and uncertainties, and actual events or results may differ materially. These risk factors include ability to commercialize and manufacture products, actions by the U.S. Food and Drug Administration, technological advances, ability to obtain rights to technology, and ability to obtain and enforce patents. These and additional risk factors are identified in the company's Securities and Exchange Commission filings, including the Forms 10-K and 10-Q and in other SEC filings.
For further information, please contact: Howard W. Robin, President & CEO of Sirna Therapeutics, Inc., +1-303-449-6500; or Amy Sullivan, Senior Vice President of Noonan Russo Presence, +1-415-677-4455, for Sirna Therapeutics, Inc.
--------------------------------------------------------------------------------
Source: Sirna Therapeutics |
